Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jan-Erik Frödin

Clinical Phase I Study With an Insulin-Like Growth Factor-1 Receptor Inhibitor: Experiences in Patients With Squamous Non-Small Cell Lung Carcinoma

Acta Oncologica

English

Related publications

Activation of Insulin-Like Growth Factor 1 Receptor in Patients With Non-Small Cell Lung Cancer

Oncotarget

Oncology

2015

English

The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation

International Journal of Molecular Sciences

Organic Chemistry

Molecular Biology

Theoretical Chemistry

Inorganic Chemistry

Computer Science Applications

English

Mutational Analysis of the Insulin-Like Growth Factor 1 Receptor Tyrosine Kinase Domain in Non-Small Cell Lung Cancer Patients

Molecular and Clinical Oncology

Cancer Research

Oncology

2015

English

Preclinical and First-In-Human Phase I Studies of KW-2450, an Oral Tyrosine Kinase Inhibitor With Insulin-Like Growth Factor Receptor-1/Insulin Receptor Selectivity

English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal

Medicine

2015

English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

English

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

World Journal of Oncology

Cancer Research

Oncology

2019

English

Phase I Clinical Trial of Human Vascular Endothelial Growth Factor Receptor 1 Peptide Vaccines for Patients With Metastatic Renal Cell Carcinoma

British Journal of Cancer

Cancer Research

Oncology

2013

English

190TiP: ELUXA 1: Phase II Study of BI 1482694 (HM61713) in Patients (Pts) With T790m-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jan-Erik Frödin

Clinical Phase I Study With an Insulin-Like Growth Factor-1 Receptor Inhibitor: Experiences in Patients With Squamous Non-Small Cell Lung Carcinoma

Related publications

Activation of Insulin-Like Growth Factor 1 Receptor in Patients With Non-Small Cell Lung Cancer

The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation

Mutational Analysis of the Insulin-Like Growth Factor 1 Receptor Tyrosine Kinase Domain in Non-Small Cell Lung Cancer Patients

Preclinical and First-In-Human Phase I Studies of KW-2450, an Oral Tyrosine Kinase Inhibitor With Insulin-Like Growth Factor Receptor-1/Insulin Receptor Selectivity

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Phase I Clinical Trial of Human Vascular Endothelial Growth Factor Receptor 1 Peptide Vaccines for Patients With Metastatic Renal Cell Carcinoma

190TiP: ELUXA 1: Phase II Study of BI 1482694 (HM61713) in Patients (Pts) With T790m-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)